Skip to content
Lurbinectedin
Zepzelca (lurbinectedin) is a small molecule pharmaceutical. Lurbinectedin was first approved as Zepzelca on 2020-06-15. It is used to treat small cell lung carcinoma in the USA.
Download report
Favorite
FDA Novel Drug Approvals 2020
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Zepzelca
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lurbinectedin
Tradename
Company
Number
Date
Products
ZEPZELCAJazz PharmaceuticalsN-213702 RX2020-06-15
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
zepzelcaNew Drug Application2020-06-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
small cell lung carcinoma—D055752—
Agency Specific
FDA
EMA
Expiration
Code
LURBINECTEDIN, ZEPZELCA, JAZZ
2027-06-15ODE-304
2025-06-15NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Lurbinectedin, Zepzelca, Jazz
77636152024-12-13DS, DPU-2836
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX69: Lurbinectedin
HCPCS
Code
Description
J9223
Injection, lurbinectedin, 0.1 mg
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Small cell lung carcinomaD055752444—212
Ovarian neoplasmsD010051EFO_0003893C56311——4
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80117———15
Breast neoplasmsD001943EFO_0003869C5032———4
Pancreatic neoplasmsD010190EFO_0003860C2522———3
SarcomaD01250923———3
Non-small-cell lung carcinomaD00228911———2
Colorectal neoplasmsD01517921———2
Endometrial neoplasmsD016889EFO_000423022———2
Neuroendocrine tumorsD018358EFO_1001901D3A.821———2
Lung neoplasmsD008175C34.9011———2
Stomach neoplasmsD013274EFO_0003897C1611———1
Show 9 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Head and neck neoplasmsD0062581————1
Female genital neoplasmsD0058331————1
Endometrioid carcinomaD0182691————1
Hepatic insufficiencyD0485501————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLURBINECTEDIN
INNlurbinectedin
Description
Lurbinectedin, sold under the brand name Zepzelca, is a medication used for the treatment of small cell lung cancer.
Classification
Small molecule
Drug classecteinascidin derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1ccc2[nH]c3c(c2c1)CCN[C@]31CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4
Identifiers
PDB—
CAS-ID497871-47-3
RxCUI—
ChEMBL IDCHEMBL4297516
ChEBI ID—
PubChem CID57327016
DrugBankDB12674
UNII ID2CN60TN6ZS (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Zepzelca - Jazz Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 478 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
26,193 adverse events reported
View more details